Tonin P N, Mes-Masson A M, Narod S A, Ghadirian P, Provencher D
Department of Medicine, McGill University and Montreal General Hospital Research Institute, Canada.
Clin Genet. 1999 May;55(5):318-24. doi: 10.1034/j.1399-0004.1999.550504.x.
The breast cancer susceptibility genes, BRCA1 and BRCA2, differ in their contribution to ovarian cancer. Recently, founder mutations in each of these genes were identified in Canadian breast cancer and breast ovarian cancer families of French ancestry. We have examined the prevalence of the founder mutations in a series of 113 French Canadian women with ovarian cancer unselected for family history. Germline mutations were found in eight of 99 invasive carcinomas and in none of the 14 tumors of borderline malignancy. Five cases carried the BRCA1 C4446T mutation and two cases carried the BRCA2 8765delAG mutation which are the most common mutations that have been described in French Canadian breast cancer and breast ovarian cancer families. All of these cases reported a family history of at least one first-degree relative with breast cancer, diagnosed below age 60 years, or with ovarian cancer. The identification of founder BRCA1 and BRCA2 mutations in ovarian cancer cases unselected for family history can facilitate carrier detection when the expected yield of a comprehensive screen may be low.
乳腺癌易感基因BRCA1和BRCA2对卵巢癌的影响有所不同。最近,在加拿大法裔血统的乳腺癌和乳腺卵巢癌家族中发现了这两个基因各自的始祖突变。我们在113名未根据家族史进行选择的法裔加拿大卵巢癌女性患者中,检测了始祖突变的发生率。在99例浸润性癌中有8例发现了种系突变,而14例交界性恶性肿瘤中均未发现。5例携带BRCA1基因的C4446T突变,2例携带BRCA2基因的8765delAG突变,这是在法裔加拿大乳腺癌和乳腺卵巢癌家族中最常见的突变。所有这些病例均报告至少有一位60岁以下被诊断为乳腺癌或卵巢癌的一级亲属的家族史。在未根据家族史进行选择的卵巢癌病例中鉴定出BRCA1和BRCA2始祖突变,当全面筛查的预期检出率可能较低时,有助于携带者的检测。